Potential clinical benefits of specific anti-myotonia treatment in DM1 include, (1) decreased muscle relaxation time, (2) restored MyHC fiber type pattern, (3) increased muscle power due to a higher proportion of mechanically stronger glycolytic fibers, (4) reduced muscle injury, (5) improved fiber size, and (6) enhanced overall muscle function. Here, MYH6 is linked to myotonic dystrophy type 1.